Enodia Therapeutics
Develops small-molecule therapies for targeted protein degradation at the point of synthesis
€20.7MSeed
Role not disclosedWE
Wallonie Entreprendre
Activity from announced rounds
Activity in this selectionEurope · Seed
Wallonie Entreprendre is the public investor identified through its Enodia announcement and Chift and Novadip coverage.
Recorded funding activity
Enodia develops protein-degradation medicines. Chift connects financial software APIs, while Novadip develops regenerative cell therapies. W.IN.G and named regional funds remain distinct from the public investor.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $24.2M 1 disclosed · full round size, not this investor’s share